Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Lipidol. 2013 Aug;24(4):307-12. doi: 10.1097/MOL.0b013e328361f62d.

The promises of PCSK9 inhibition.

Author information

1
The University of New South Wales, Sydney, New South Wales, Australia.

Abstract

PURPOSE OF REVIEW:

In the past 10 years, the LDL receptor inhibitor proprotein convertase subtilisin kexin type 9 (PCSK9) has emerged as a validated target for lowering plasma LDL cholesterol levels. Here we review the most recent reports on PCSK9 out of a total of 500 publications published in print or online before March 2013 and indexed on PubMed.

RECENT FINDINGS:

All published in 2012, phase I and II clinical trials demonstrate that fully human monoclonal antibodies targeting PCSK9 dramatically reduce LDL-C and enable patients to reach their target goals, without severe or serious safety issues.

SUMMARY:

This review summarizes the discovery of PCSK9, its original mode of action as a secreted inhibitor of the LDL receptor, as well as its genetic regulation by statins. We then focus on the major results from the 2012 phase I and II PCSK9 inhibitor clinical trials. We also review the recent in-vivo studies demonstrating the potential cardiovascular benefits of long-term PCSK9 inhibition and discuss its potential side-effects.

PMID:
23817198
DOI:
10.1097/MOL.0b013e328361f62d
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wolters Kluwer
    Loading ...
    Support Center